• Apicidin: HDAC Biology, Cancer and Reproductive Risk

  2026-10-07

  Apicidin is a fungal metabolite and histone deacetylase inhibitor studied in epigenetics, cancer biology, angiogenesis, parasitology and reproductive toxicology. This overview compares the evidence, separates reported findings from interpretation, and explains why in vitro activity and supplier claims do not establish clinical or environmental risk.

• Toremifene Citrate: An Evidence-First Research Framework

  2026-10-06

  Toremifene Citrate is an oral selective estrogen receptor modulator with value across breast cancer research and endocrinology research. This evidence-first framework separates receptor binding, cellular response, translational interpretation, and clinical provenance to support more rigorous hormone receptor modulation studies.

• Syringin in RCC: EGFR/PI3K/Akt and Sunitinib

  2026-10-06

  The reference study presents Syringin as a candidate natural product for renal cell carcinoma (RCC), combining computational target analysis with cell-based evidence of reduced growth, migration, and survival. Its most important implication is that Syringin may increase RCC sensitivity to Sunitinib through effects associated with the EGFR/PI3K/Akt pathway, although the evidence remains preclinical and requires validation beyond cellular models.

• EZ Cap™ Cas9 mRNA (m1Ψ): Evidence Guide

  2026-10-05

  EZ Cap™ Cas9 mRNA (m1Ψ) is an in vitro transcribed Cas9 mRNA with Cap1, m1Ψ, and a poly(A) tail. The product dossier supports a mechanistic rationale for translation and immune-response research, but it does not independently establish editing efficiency, specificity, or clinical performance in a defined cell type.

• MOG (35-55): Evidence and Research Context

  2026-10-05

  MOG (35-55) is a myelin oligodendrocyte glycoprotein peptide used as an antigenic tool in experimental autoimmune encephalomyelitis research. The supplied 2025 study links PARP7 inhibition with restored type I interferon signaling and reduced EAE severity in mice, but it does not establish that MOG (35-55) directly regulates PARP7 or treats human multiple sclerosis.

• tFUS, Nespas, and SHP2 in Ischemic Stroke

  2026-10-04

  A 2025 International Immunopharmacology study links transcranial focused ultrasound stimulation with reduced NLRP3-mediated neuroinflammation after experimental ischemic stroke. Its central contribution is a mechanistic model in which tFUS influences the Nespas/miR-383-3p/SHP2 axis in microglia, while the evidence remains limited to rat and cell-based systems.

• EZ Cap™ Cas9 mRNA: A Translational Evidence Framework

  2026-10-03

  EZ Cap™ Cas9 mRNA (m1Ψ) combines a Cap1 structure, m1Ψ modification, and a poly(A) tail for research on transient CRISPR-Cas9 activity. This evidence-focused guide explains how to interpret its molecular design, translational relevance, and limitations without confusing product specifications with demonstrated efficacy.

• From Tag Cleavage to Nuclear Architecture

  2026-10-02

  A translational perspective on how PreScission Protease can improve recombinant protein quality for mechanistic studies of Keap1, lamin Dm0, and chromatin architecture.

• Position-3 GnRH Antagonists: Synthesis and Activity

  2026-10-01

  Samant and colleagues examined how replacing the position-3 residue of degarelix with stereoisomeric 3-(2-methoxy-5-pyridyl)-alanine affected GnRH receptor antagonism and duration of action. The D-isomer preserved strong in vitro potency, whereas the L-isomer was substantially weaker, and both analogs were short-acting in the castrated-male-rat assay.

• GnRH Antagonists with 2-OMe-5Pal at Position 3

  2026-10-01

  Samant and colleagues investigated how replacing position 3 of degarelix with D- or L-3-(2-methoxy-5-pyridyl)-alanine changes GnRH receptor antagonism and in vivo persistence. The D-isomer retained strong in vitro activity, whereas the L-isomer was weaker, and both analogs were short-acting in castrated male rats, separating receptor potency from pharmacokinetic duration.

• Tigecycline Workflows for Resistant-Pathogen Research

  2026-09-30

  Build stronger resistant-pathogen assays with Tigecycline, a glycylcycline antibiotic that links 30S ribosomal inhibition to isolate-specific susceptibility testing. This guide translates carbapenemase-transmission findings into practical workflows for MRSA, GISA, Enterobacterales, and plasmid-resistance studies while separating evidence-backed observations from optimization starting points.

• SN-38 Disrupts FUBP1–FUSE DNA Binding

  2026-09-30

  The reference study identifies camptothecin and its active metabolite SN-38 as inhibitors of the FUBP1–FUSE DNA interaction, adding a transcriptional mechanism to their established topoisomerase I activity. Its combination of biochemical screening and hepatocellular carcinoma cell analyses provides a framework for separating direct disruption of oncogenic DNA regulation from downstream replication stress and apoptosis.

• N1-Methyl-Pseudouridine-5'-Triphosphate Workflow

  2026-09-29

  Build more stable, efficiently translated RNA for mechanistic studies, co-formulated mRNA experiments, and vaccine-development workflows with N1-Methyl-Pseudouridine-5'-Triphosphate. This practical guide connects reagent handling and in vitro transcription optimization to the co-encapsulated antigen–adjuvant mRNA strategy reported in influenza research.

• Thiothixene: From D2 Blockade to Efferocytosis

  2026-09-29

  Thiothixene is a typical antipsychotic agent with an emerging macrophage biology: it enhances continual efferocytosis through Stra6L, vitamin A signaling, and Arginase 1. This article translates the pivotal findings into practical assay-design decisions while separating established pharmacology from early translational opportunities.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-28

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin reagent for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell and tissue samples. It supports cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but it is not a general membrane stain, antibody substitute, or probe for non-carbohydrate targets.

8017 records 1/535 page Next 12345 下5页 Last page